REC-1 SMAD/TGFbeta Reporter (Luc) stable cell line
REC-1 SMAD/TGFbeta Reporter (Luc) cells are derived from the human B-cell lymphoma cell line REC-1 by stably integration of a SMAD/TGFbeta firefly luciferase reporter construct. REC-1 is derived from a patient with mantle cell lymphoma (MCL), making it a valuable model for studying this specific type of lymphoma. REC-1 cells are used to investigate the molecular pathways involved in MCL pathogenesis, including the role of cyclin D1 in cell cycle regulation, as well as to evaluate the efficacy of new therapeutic agents, including chemotherapy and targeted therapies. REC-1 SMAD/TGFbeta Reporter (Luc) cells stably express firefly luciferase under the control of the SMAD/TGFbeta response elements, can be used for monitoring the activity of TGF?/SMAD signaling pathway.
Product Specifications
No additional specifications available.
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Ergotamine for system suitability - * prec (Y0001851)
Cacna1e sgRNA CRISPR Lentivector (Mouse) (Target 2)
MCP2 (Macrophage/Monocyte Chemotactic Protein 2, Chemokine C-C Motif Ligand 8, CCL8, HC14, Monocyte Chemotactic Protein 2, Small Inducible Cytokine A8 Precursor, SCYA8, SCYA10) discontinued